Advanced Filters
noise

PARIS cedex 14, France Clinical Trials

A listing of PARIS cedex 14, France clinical trials actively recruiting patients volunteers.

Found 1,555 clinical trials

Bariatric SUrgery With Mesh REpair of Ventral Hernia: a Randomized Controlled Trial

The primary objective of the study is to demonstrate that hernia recurrence (VH) repair with non absorbable mesh concomitant to Bariatric Surgery (BS) decreases the risk of VH, with or without surgical repair, during the first two years after BS when compared to VH suture repair without mesh. As secondary …

18 - 60 years of age All Phase 3

Repertoire and Properties of Anti-drug Antibodies Involved in Immediate Hypersensitivity in the Operating Room

Acute per-anesthetic hypersensitivity reaction (HSA-PA) is a rapidly occurring systemic reaction following injection of a drug during anesthesia (mortality between 3 and 9%). The substances responsible for these reactions in France are curare in 60% of cases, followed by antibiotics. The main mechanism mentioned is an immediate systemic hypersensitivity immune …

18 - 70 years of age All Phase N/A
M Mélanie FROMENTIN, MD

Evaluating the Benefit of Hypnoanalgesia Versus Neuroleptanalgesia During Hand Surgery

This is a single-center, prospective, randomized, open-label study of two parallel groups of patients undergoing hand surgery: Group 1: locoregional anesthesia + neuroleptanalgesia Group 2: locoregional anesthesia + hypnoanalgesia Therapeutic benefit is based on VAS assessment of intraoperative anxiety.

18 - 80 years of age All Phase N/A
O Olivier ORMEZZANO

Women Hypertensive and Young-Renal Denervation

Renal denervation is a new method to lower blood pressure (BP) in hypertensive patients by reducing the impact of sympathetic nervous system. Its efficacy has been demonstrated in resistant hypertension and in lowering BP in essential hypertension as compared to a sham procedure in untreated hypertensive patients. This procedure is …

18 - 40 years of age Female Phase N/A

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.

18 - 75 years of age Female Phase 2
G Gregory Torkomian

Platelets Activation in Brain Neoplasms

Platelets are primarily known for their central role in primary hemostasis. However, they are increasingly recognized for their participation in various non-hemostatic processes, such as cancer progression and clinical expression. Experimental and clinical data indicate that the involvement of platelets in the pathophysiology of cancer goes far beyond the realm …

18 years of age All Phase N/A
E Etienne PUYMIRAT

DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

Recent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors. There are no existing randomized clinical trials evaluating the efficacy and safety of dapagliflozin (nor any other SGLT2-inhibitor) to limit cardiac remodeling in …

18 years of age All Phase 3
C Clémence Basse, MD

Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)

The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).

18 years of age All Phase N/A
L LEDOUX Severine

Extending Time Without Diabetes After Bariatric Surgery: a Trial Comparing the Metformin Addition or Not to Standard Care

This study is a randomized trial that evaluates the effect of metformin addition or not to standard care on the duration of diabetes remission after bariatric surgery.

18 - 70 years of age All Phase 3
B Benjamin CHAIGNE, MD

Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

The purpose of this study is to determine whether itacitinib is safe and effective in the treatment of systemic sclerosis in adults.

18 years of age All Phase 2

Simplify language using AI